546-67-8

应用筛选条件

关键词:'546-67-8'

显示 1-1 共 1 条结果关于 "546-67-8" 范围论文

Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study.

Charles J Ryan et al.

The Lancet. Oncology, 16(2), 152-160 (2015-01-21)

Abiraterone acetate plus prednisone significantly improved radiographic progression-free survival compared with placebo plus prednisone in men with chemotherapy-naive castration-resistant prostate cancer at the interim analyses of the COU-AA-302 trial. Here, we present the prespecified final analysis of the trial, assessing

1/1